About Alchemab
Alchemab is a biotech company focused on discovering and developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies.
Our approach
Unique and Unbiased Approach
By mapping antibody repertoire differences between resilient and diseased individuals, we can identify protective antibodies conserved across patient populations, uncover the binding targets of the antibodies and subsequently develop therapeutic candidates that replicate the protective effect.
Convergent Protective Antibody Responses
Our highly differentiated drug discovery engine uses high-quality patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in individuals that are susceptible but resilient to specific diseases.
Therapeutics for Hard-to-Treat Diseases
We are building our transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions and infectious diseases.
Patient Sample Hub
The patient samples that power our engine are made available through key partnerships and collaborations with patient representative groups, academics and biobanks.
Our Patient Sample Hub is continuously evolving, and we are always interested in exciting collaborations.
Team
Alchemab is led by a highly experienced management team and has an extended team of scientific founders and collaborators contributing cutting-edge technology and a deep understanding of antibody repertoires, bringing together a wide range of expertise from the fields of neuroscience, oncology, infectious diseases and computational biology.
Alex Leech
CEO
Alex joined Alchemab as founding CEO in 2019, bringing extensive biotechnology and pharmaceutical leadership experience. He is a serial biotechnology CEO and in 2016 he led the sale of European dermatology company Creabilis Therapeutics. Alex is an experienced company builder, a Venture Partner at SV Health Investors and a non executive Director of Zarodex Therapeutics.
Jane Osbourn
CSO
Former VP of R&D at MedImmune (Astrazeneca), former Chair of the BIA. OBE for services to drug discovery & development and Lifetime Achievement Award from Scrip.
Olivia Cavlan
Head of Business & Operations
Olivia is an experienced biotech leader, former McKinsey and QuantumBlack Partner focused on biopharmaceutical analytics and private equity, and previously an academic clinician specialised in paediatric infectious diseases.
Gavin Kilpatrick
Head of Neuroscience and Academic Liaison
30 years’ experience of drug discovery and development in biotechnology and pharmaceutical sectors. Senior management positions at GSK, CeNeS, Roche and Takeda.
Get in touch
Alchemab Therapeutics
55-56 Russell Square
Bloomsbury
WC1B 4HP
Follow us:
Twitter: twitter.com/AlchemabTx
LinkedIn: linkedin.com/company/alchemab-therapeutics-ltd
© 2020 Alchemab. All rights reserved.